Arizona Biotech Advances Multiple Cell Therapies


November 17, 2023 ( Newswire) Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data.

Phoenix, Arizona-based Creative Medical Technology Holdings Inc. (CELZ:NASDAQ) provided clinical and operational updates across its pipeline of cell-based therapies, noted Roth MKM analyst Dr. Jonathan Aschoff in a November 15 research report.


Aschoff reiterated a Buy rating and US$30 price target on Creative Medical.

Multiple Clinical Programs Progressing

Creative Medical is advancing Phase 1/2 trials of CELZ-201-DDT for chronic lower back pain and CELZ-201 for type 1 diabetes. The company also reported positive one-year data for CELZ-001 in type 2 diabetes.


According to Aschoff, CELZ-201-DDT showed over 90% pain reduction and 80% narcotics reduction in a pilot study, supporting the upcoming Phase 1/2 trial. Enrollment is underway for the CELZ-201 type 1 diabetes study.

The analyst sees Creative Medical’s ImmCelz platform, which activates a patient’s own cells, as a key value driver. The company made progress optimizing ImmCelz and expects to enter the clinic for autoimmune disorders.

Funded Through 2024 with Over US$12 Million Cash


Creative Medical maintained a strong cash position of US$12 million at the end of Q3 2023, providing a runway through 2024 based on the analyst’s estimates.

Significant Upside from Regenerative Medicine Pipeline

Roth Capital’s US$30 price target on Creative Medical implies over 600% upside potential for the stock. The firm’s valuation is based on a discounted cash flow analysis of projected revenues from the company’s pipeline candidates.

In summary, the analyst sees Creative Medical’s progress across multiple cell therapy programs, combined with its cash balance, as positioning the company for upside as data catalysts approach.

More Info: Newswire

This news is published on the Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy:

That’s all it takes to get an article published on Investor Ideas – Learn More - A Leading Global Investor Website for Biotech Industry Stocks

Buy a biotech guest post on

Source link

Leave a Comment